Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

A study to evaluate the efficacy and safety of tislelizumab combined with bevacizumab and platinum-based pemetrexed in the treatment of naïve patients with advanced non-squamous non-small cell lung cancer with sensitive EGFR mutations and high PD-L1 expression Prospective, open-label, single-arm phase II clinical study; Research purposes: Main purpose: To evaluate the median progression-free rate of tislelizumab combined with bevacizumab and platinum pemetrexed in treatment-naïve advanced non-small cell lung cancer patients with sensitive EGFR mutations and high PD-L1 expression Survival (middle progression free survival, mPFS) Secondary purpose: * Evaluation of objective response rate (ORR) according to RECIST version 1.1; * Evaluation of disease control rate (DCR) according to RECIST version 1.1; * Assess overall survival (OS); * Assess Duration of Response (DOR); * Evaluate the safety of the treatment using NCI-CTCAE v5; Exploratory Purpose: • Assess potential predictive biomarkers.